2023年8月12日 · Y332D could simultaneously block TGF-β and VEGF signalings. In comparison with the monotherapies, Y332D combined with PD-1 blockade exerts superior antitumor effect through improving immune microenvironment.

2022年12月1日 · Here, we review these pathways' functions, their roles in immunosuppression, and the currently available therapies that target them. We also discuss recent developments in the targeting of TGF-β using a specific antibody class termed trap antibody.

2023年8月12日 · In order to optimize the antitumor efficacy of PD-1/PD-L1 antibodies, we developed the first novel anti-TGF-β/VEGF bispecific antibody Y332D, which can simultaneously block both immune-negative signals TGF-β and VEGF in the tumor microenvironment.

2008年2月18日 · Given the neurological findings in patients treated with VEGF-neutralizing therapy (bevacizumab) and in patients with severe preeclampsia, which is mediated by soluble VEGF receptor 1/soluble Fms-like tyrosine kinase receptor 1 and soluble endoglin, a TGF-beta signaling inhibitor, we investigated the roles of VEGF and TGF-beta in choroid plexus ...

2016年6月16日 · VEGF and/or TGF-β silencing also restored tumor sensitivity to tumor-specific cell therapies and markedly improved the efficacy of anti-PD-1/anti-CTLA-4 treatment. Thus, TGF-β and VEGF cooperatively control the tolerant environment of tumors and are targets for improved cancer immunotherapies.

2024年3月24日 · Therapeutic agents targeting TGF-β and VEGFA, the representative pathways of IPRES, may synergize with existing immunotherapies to overcome ICB resistance. This review summarizes existing literatures on recent strategies that combine ICB with therapeutics targeting the TGF-β and VEGFA pathways.

Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β pathways play an important role in the development and function of the TME, contributing to the immunosuppressive status of TME.

tgf-β诱导血管内皮生长因子（vegf）的表达，vegf是体外重要的血管生成因子。 在胶质母细胞瘤、HCC和CRC模型中，使用TGF-β途径抑制剂的治疗降低了微血管密度并抑制了肿瘤血管的形成。

2020年3月10日 · In the present study, we demonstrate that TGF-β1 stimulates VEGF expression in and secretion from both immortalized human granulosa-lutein (hGL) cells and primary hGL cells. Our results...

2023年8月20日 · 近日， 华中科技大学同济医学院附属同济医院梅齐、楚倩和吴孔明团队在知名期刊Journal of Hematology & Oncology发文，证实Y332这款创新双抗可通过高效抑制TGF-β和VEGF，逆转免疫微环境抑制及癌细胞的上皮-间质转化（EMT）等过程，从而实现与PD-1抑制剂的高度协同增效、强力抑癌。 论文首页截图. 关注免疫联合治疗的读者们，对VEGF促血管生成功效外的免疫抑制作用应该不会陌生，不然近些年免疫+抗血管方案也不会在肝癌等瘤种中连战连 …